Abstract
Objectives: The aim of the present study was to investigate the effects of captopril vs amlodipine on blood pressure, BMI, serum glucose concentration and lipid profile in a number of overweight and obese hypertensive patients.
Methods: This study was conducted on 2 groups of overweight and obese newly diagnosed stage 1 hypertensive patients; captopril group involves 42 patients who kept on captopril monotherapy and amlodipine group involves 41 patients who kept on amlodipine monotherapy. Another 40 apparently healthy normotensive individuals were used as a control group. The patients were placed on captopril or amlodipine for 8 weeks. Data were collected from each individual before and at the end of the trial including systolic and diastolic BP, body weight, BMI, fasting serum glucose and lipid profile.
Results: Comparisons of the values of the measured parameters of the control group with those of the captopril or amlodipine group before drug administration yield highly significant differences. After 8 weeks of treatment with captopril or amlodipine the measured parameters are significantly reduced. Comparison of the percent variation of the studied parameters of captopril group and those of amlodipine group revealed no significant differences except for FSG where a higher reduction was obtained with captopril .
Conclusion: This study demonstrated that both captopril and amlodipine are effective agents in the treatment of hypertension in overweight and obese patients. In addition, both drugs have beneficial effects on body weight, serum glucose concentration and lipid profile.

Key words: Overweight, obesity, hypertension, captopril, amlodipine